Thursday, May 10, 2012
The US Food and Drug Administration (FDA) has issued a safety alert to warn people living with MS of the risks of serious injury and death associated with the “liberation procedure” used to treat chronic cerebrospinal venous insufficiency (CCSVI).
Chronic cerebrospinal venous insuf...
Test Your MS Knowledge 
10 Symptoms That Could Be MS 
10 Foods That Fight Inflammation 
Unusual Multiple Sclerosis Symptoms 
More quick thoughts on the topic of the FDA announcement from my Brass and Ivory blog:
How do you get the world to take notice of a controversial theory and treatment regarding MS and narrowed veins? You get the FDA to issue a safety warning.
Only if you were completely separated from the online MS community yesterday did you miss the alert coming from the FDA regarding Chronic Cerebrospinal Venous Insufficiency (CCSVI) and the "liberation procedure" used to open narrowed veins.
CCSVI has been discussed widely throughout the MS community since mid-2009 (yes, even before the Canadian news picked it up in October or November that year). There has been a huge firestorm of patient advocacy which has pushed for treatment...and research...for CCSVI.
True that there are three documented cases of patients who have died following CCSVI treatment, two involving stent migration following early treatment/experiments in California. Last April, a Canadian woman died five days following treatment in Costa Mesa.
The FDA announcement does not reference any NEW cases of death, but that will not matter to our friends, family, and coworkers who are going to be asking us (or warning us) about the controversial theory/treatment.
The bottom line of the FDA announcement includes:
These are all good words of advice for any health-related decisions we make.